Literature DB >> 8209917

Abnormal bile acids in the Smith-Lemli-Opitz syndrome.

M R Natowicz1, J E Evans.   

Abstract

The urinary bile acids from four patients with Smith-Lemli-Opitz (SLO) syndrome were analyzed by continuous flow fast atom bombardment mass spectrometry. Two types of abnormalities were noted: (1) a deficiency of normal bile acids (cholenoates) and (2) the presence of abnormal species postulated to be cholenoates and cholestenoates. The finding of abnormal urinary bile acids in children with SLO syndrome led to further investigation of the cholesterol metabolic pathway and to the delineation of a new inborn error of metabolism, deficient conversion of 7-dehydrocholesterol to cholesterol [Irons et al., 1993]. The abnormalities of urinary bile acids, if confirmed by further structural analyses and studies of additional patients, provide an explanation for various aspects of the gastro-intestinal abnormalities and growth retardation noted in SLO syndrome and suggest that exogenous bile acid replacement may play an important role in the therapy of patients with this syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8209917     DOI: 10.1002/ajmg.1320500413

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  16 in total

Review 1.  Malformation syndromes caused by disorders of cholesterol synthesis.

Authors:  Forbes D Porter; Gail E Herman
Journal:  J Lipid Res       Date:  2010-10-07       Impact factor: 5.922

2.  Disorders of cholesterol metabolism and their unanticipated convergent mechanisms of disease.

Authors:  Frances M Platt; Christopher Wassif; Alexandria Colaco; Andrea Dardis; Emyr Lloyd-Evans; Bruno Bembi; Forbes D Porter
Journal:  Annu Rev Genomics Hum Genet       Date:  2014       Impact factor: 8.929

Review 3.  The Smith-Lemli-Opitz syndrome.

Authors:  R I Kelley; R C Hennekam
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

4.  Statins for Smith-Lemli-Opitz syndrome.

Authors:  Rami A Ballout; Simona Bianconi; Alicia Livinski; Yi-Ping Fu; Alan T Remaley; Forbes D Porter
Journal:  Cochrane Database Syst Rev       Date:  2020

Review 5.  Smith-Lemli-Opitz syndrome: a treatable inherited error of metabolism causing mental retardation.

Authors:  M J Nowaczyk; D T Whelan; T W Heshka; R E Hill
Journal:  CMAJ       Date:  1999-07-27       Impact factor: 8.262

Review 6.  Smith-Lemli-Opitz syndrome.

Authors:  Andrea E DeBarber; Yasemen Eroglu; Louise S Merkens; Anuradha S Pappu; Robert D Steiner
Journal:  Expert Rev Mol Med       Date:  2011-07-22       Impact factor: 5.600

7.  Sterols and oxysterols in plasma from Smith-Lemli-Opitz syndrome patients.

Authors:  William J Griffiths; Jonas Abdel-Khalik; Peter J Crick; Michael Ogundare; Cedric H Shackleton; Karin Tuschl; Mei Kwun Kwok; Brian W Bigger; Andrew A Morris; Akira Honda; Libin Xu; Ned A Porter; Ingemar Björkhem; Peter T Clayton; Yuqin Wang
Journal:  J Steroid Biochem Mol Biol       Date:  2016-03-11       Impact factor: 4.292

Review 8.  Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders.

Authors:  Melissa D Svoboda; Jill M Christie; Yasemen Eroglu; Kurt A Freeman; Robert D Steiner
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-10-05       Impact factor: 3.908

9.  Mutations in the human sterol delta7-reductase gene at 11q12-13 cause Smith-Lemli-Opitz syndrome.

Authors:  C A Wassif; C Maslen; S Kachilele-Linjewile; D Lin; L M Linck; W E Connor; R D Steiner; F D Porter
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

10.  Lipidomic analysis of the retina in a rat model of Smith-Lemli-Opitz syndrome: alterations in docosahexaenoic acid content of phospholipid molecular species.

Authors:  David A Ford; Julie K Monda; Richard S Brush; Robert E Anderson; Michael J Richards; Steven J Fliesler
Journal:  J Neurochem       Date:  2007-12-21       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.